Unfortunately, compounded oral tirzepatide, often misunderstood as a viable option, is not covered under insurance due to its lack of FDA approval
One in 8 American adults reports using a glucagon-like peptide 1 receptor agonist (GLP-1RA) medication, and prescriptions continue to increase due to these drugs effectiveness in reducing cardiovascular mortality and treating diabetes and obesity
Some distributors says they can no longer get their products into Canada
Hypoglycemia represents another potential risk, primarily in patients taking tirzepatide in combination with insulin or sulfonylureas
Wipe Properly: After using the toilet, always wipe from front to back
2025, "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review," HSS J